Ascendis Pharma A/S Q1 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : I have one on TransCon PTH. Just are has suggested that hypoparathyroidism patients are very complex to treat on standard of care supplements. Could you just maybe share some of the feedback that you're getting from the investigators on your Phase II study about their experience using TransCon PTH, especially now that we're kind of starting to get beyond that titration period in the open label extension? And are you hearing that it's simplifying treatment of these patients for them? And are their patients pretty excited about it now that they've been moved on to active from placebo for some of them? And then just, would you expect that 58 of 59 that are continuing now to continue on into, I guess, the future based on this -- the feedback from your investigators? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. MAY 19, 2020 / 8:30PM, ASND - Q1 2020 Ascendis Pharma A/S Earnings Call

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : All right. And just as a follow up also. You mentioned on your last call that you were planning some FDA discussions around breakthrough designation for TransCon PTH. I guess, has anything changed in your thinking on whether you'll apply for breakthrough designation? And maybe if you can just walk us through quickly some of the most important data points from the TransCon PTH study that demonstrate that it might have a substantial improvement over standard of care supplements?